Oxytetracycline

Producers shown on SFDA

(Record date:08/11/2021）

Producers shown on EP

Not showing any

Producer:Jinhe Biotechnology Co., Ltd. is a joint-stock enterprise focusing on the production and sales of aureomycin premix and animal health products.

At present, the company has a fermentation volume of 5914m3, which has the advantages of fermentation scale of veterinary antibiotic series products, and its core product aureomycin premix has an annual comprehensive production capacity of 55000 tons. The enterprise has passed the GMP acceptance of national veterinary drug enterprises and passed the quality acceptance of the Federal Food and Drug Administration (FDA) for seven consecutive times.

Staff size:About 2100 people

Registered capital:RMB 780 million 400 thousand

Producer:Inner Mongolia Kaisheng Biotechnology Co., Ltd. was founded in 2009. At present, Kaisheng enterprise has a total asset of 556 million yuan and covers an area of more than 1000 mu. At present, the company can produce 120000 tons of corn starch, 9000 tons of corn gluten powder, 6000 tons of corn slurry, 12000 tons of corn germ and 15000 tons of corn fiber. It also has the largest modern shimycin with an annual output of 6000 tons in China Production base of chlortetracycline.
Staff size:50-99 people

Registered capital:RMB 200 million

Website: 

Producer:Hebei Jianmin Starch Sugar Co., Ltd. was founded in 1994. The company mainly produces corn starch, edible glucose, oxytetracycline (API), oxytetracycline hydrochloride, injection grade oxytetracycline, streptomycin sulfate and other by-products.

The company is ISO9001 quality management system certification, pharmaceutical GMP certification, EU cos certification and US FDA certification.

Staff size:About 50 people
Registered capital:RMB 80 million

Producer:Shandong Qifa Pharmaceutical Co., Ltd. is a biopharmaceutical base invested by Qilu Pharmaceutical Co., Ltd. in 1987, mainly producing microbial drugs. The company covers an area of about 200000 square meters and produces more than 8000 tons of microbial drugs per year.

The company's main products have passed FDA, EDQM and APVMA certification.

Staff size:600-699 people

Registered capital:RMB 73.33062 million

Website: http://www.qilupharma.com

Producer:The biological branch of Datong Tongxing antibiotic Co., Ltd. was established in 2008. Datong Tongxing antibiotic Co., Ltd. is a joint-stock enterprise specializing in the production of antibiotic APIs. The company organizes production in strict accordance with GMP standards, with an annual output of 4000 tons of oxytetracycline.
Staff size:200-299 people

Registered capital:200-299 persons
Website:

Producer:Inner Mongolia Huashu Biological Technology Co., Ltd. was established in 2014, with a total area of 1000 mu, a fermentation volume of 5000 m and an annual output of 6000 tons of soil alkali.

The company has obtained domestic drug production license, drug production license and veterinary drug GMP certificate. The company has completed FDA registration in the United States with VMF registration number of 6150. At the same time, the company is undergoing EU COS certification.

Staff size:200-299 people

Registered capital:RMB 70 million

Website:

The company's main products have passed the national GMP certification and EU CEP certification, colistin sulfate has passed the German eu-gmp certification, oxytetracycline series products have passed the U.S. FDA certification, and dihydrostreptomycin has passed the aseptic CEP certification. The company is the only state-owned enterprise in the competition of similar products, with a total production capacity of more than 10000 tons. Its products sell well all over the country and are exported to Europe, America, Southeast Asia, the Middle East, India, North Africa, South America and other dozens of countries and regions, of which colistin sulfate accounts for more than 70% of the global market; Streptomycin sulfate accounts for about 60% of the global market share; Oxytetracycline series products occupy the main international high-end market share.

Staff size:500-599 people

Registered capital:RMB 46.995196 million

Website: https://www.dcpharma.cn

For supply and market information, please feel free to contact Mr. Paul, paulzhang@yinuopharmchem.com, WhatsApp: +86 18402846978